Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension

Rosenbaum, David; Girerd, Xavier

doi:10.1185/03007995.2011.644626

Cited by 4 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About 0.19% patients had serious adverse events and none were reported due to study drug (63). Fogari et al reported 3.9% of patients in an olmesartan/HCTZ 40/12.5 mg/day group had drug related adverse events compared to 0.7% in the olmesartan 40 mg/day monotherapy treatment arm.…”

Section: Safety and Tolerability Of Arbs In Hypertensionmentioning

confidence: 99%

The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases

2014

View full text Add to dashboard Cite

All national guidelines for the management of hypertension recommend angiotensin receptor blockers (ARBs) as an initial or add-on antihypertensive therapy. The 8 available ARBs have variable clinical efficacy when used for control of hypertension. Additive blood pressure (BP) lowering effects have been demonstrated when ARBs are combined with thiazide diuretics or dihydropyridine calcium channel blockers, augmenting hypertension control. Furthermore, therapeutic use of ARBs goes beyond their antihypertensive effects with evidence-based benefits in heart failure and diabetic renal disease particularly among ACE inhibitor intolerant patients. On the other hand, combining renin-angiotensin system blocking agents, a formerly common practice among medical subspecialists focusing on the management of hypertension, have ceased to do so as there is not only evidence of cardiovascular benefit, but modest evidence of harm, particularly with regard to renal dysfunction. The ARBs are very well tolerated as monotherapy as well as in combination with other anti-hypertensive medications that improve adherence to therapy and have become a mainstay in the treatment of stage 1 and 2 hypertension.

show abstract

Section: Safety and Tolerability Of Arbs In Hypertensionmentioning

confidence: 99%

The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases

2014

View full text Add to dashboard Cite

show abstract

Olmesartan medoxomil: a guide to its use as monotherapy or in fixed-dose combinations with amlodipine and/or hydrochlorothiazide

Lyseng‐Williamson

2016

Drugs Ther Perspect

View full text Add to dashboard Cite

Current World Literature

2012

Current Opinion in Nephrology &Amp; Hypertension

View full text Add to dashboard Cite

Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension

Abstract: Study 1: EudraCT Number: 2006-003876-37; ClinicalTrials.gov identifier: NCT00430508; Study 2: EudraCT Number: 2006-003876-28; ClinicalTrials.gov identifier: NCT00430950.

Cited by 4 publications

References 19 publications

The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases

The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases

Olmesartan medoxomil: a guide to its use as monotherapy or in fixed-dose combinations with amlodipine and/or hydrochlorothiazide

Current World Literature

Contact Info

Product

Resources

About